Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the...

The employment of John Richards as CEO of the Joint Corp. (NASDAQ:JYNT) has been terminated by mutual agreement, effective June 30.  Mr. Richards also resigned as a director. Peter Holt, who was previously COO, was...

At the annual meeting of Titan Medical (TSX:TMD), shareholders voted against reelecting John Hargrove, CEO and chairman, as a director. Mr. Hargrove received 42% of votes cast in favor of reelection and 58% against...

Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has appointed Marcos Rodriguez as chief accounting officer. Mr. Rodriguez brings over 17 years of diversified accounting experience to the company. Prior to joining Nobilis, he...

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.Mr...

Rigel Pharmaceuticals (NASDAQ:RIGL) has appointed Dr. Anne-Marie Duliege, as CMO, replacing Dr. Elliott Grossbard, who is retiring after 14 years with the company.Dr. Grossbard will remain with the company, advising on...

Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also...

Closely-held Soricimed Biopharma has named Bob Cory as VP of business development and appointed Tom Reeves, a director, as chairman. Dr. Cory has over 20 years of business and corporate development leadership experience...

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director.Dr. Rubin is a leading...

Carol Ann Werther has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.Ms. Werther joins HCW with over 20 years of experience in the biotechnology sector...